Wolverine Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Wolverine Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Buy	3,289 +1,478	+82%	+$28	﹤0.01%	1652
2026 Q1	$47	Hold	1,811	–	–	﹤0.01%	1662
2025 Q4	$57	Hold	1,811	–	–	﹤0.01%	1632
2025 Q3	$42	Sell	1,811 -2,809	-61%	-$94	﹤0.01%	1576
2025 Q2	$153	Hold	4,620	–	–	﹤0.01%	1564
2025 Q1	$161	Sell	4,620 -4,035	-47%	-$226	﹤0.01%	1529
2024 Q4	$651	Sell	8,655 -6,864	-44%	-$414	﹤0.01%	1534
2024 Q3	$558	Buy	15,519 +200	+1%	+$7	﹤0.01%	1559
2024 Q2	$726	Sell	15,319 -7,464	-33%	-$276	﹤0.01%	1560
2024 Q1	$888	Sell	22,783 -27	-0.1%	-$1	﹤0.01%	1525
2023 Q4	$688	Buy	22,810 +10,045	+79%	+$605	﹤0.01%	1638
2023 Q3	$893	Buy	12,765 +3,400	+36%	+$313	﹤0.01%	1707
2023 Q2	$977	Sell	9,365 -3,425	-27%	-$358	﹤0.01%	1643
2023 Q1	$460	Hold	12,790	–	–	﹤0.01%	1761
2022 Q4	$601	Buy	12,790 +11,169	+689%	+$681	﹤0.01%	1982
2022 Q3	$0	Buy	+1,621	New	+$193	﹤0.01%	2494
2021 Q3	–	Sell	-11,855	Closed	-$10K	–	2299
2021 Q2	$10K	Sell	11,855 -35,209	-75%	-$25.6K	﹤0.01%	1994
2021 Q1	$28K	Buy	+47,064	New	+$48.9K	﹤0.01%	1727

Other funds holding SABSW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Wolverine Asset Management's SABSW Position: Q2 2026 in Review

Wolverine Asset Management increased its SAB Biotherapeutics Warrant (SABSW) stake by 82% in Q2 2026, buying an estimated $28 and bringing the position to 3,289 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Wolverine Asset Management first reported a position in SABSW in Q1 2021 and has held it in 18 quarters since. The position peaked at $28K in Q1 2021. 8 funds tracked by Wall St. Rank hold SABSW as of Q2 2026.

Wolverine Asset Management held 3,289 shares of SAB Biotherapeutics Warrant worth $42 as of Q2 2026.
Wolverine Asset Management bought 1,478 SAB Biotherapeutics Warrant shares in Q2 2026, an estimated $28.
SAB Biotherapeutics Warrant made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1652 holding.
Wolverine Asset Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 18 quarters since.
Wolverine Asset Management's SAB Biotherapeutics Warrant position peaked at $28K in Q1 2021.
8 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.